B0387 - Baseline Demographics and Disease Characteristics of Patients With Ulcerative Colitis Who Responded to Vedolizumab at Week 6

Andres Yarur, MD¹, Vipul Jairath, MBChB, DPhil, MRCP², Edward V. Loftus, MD, FACG³, Bruce E. Sands, MD, MS, FACG⁴, Sharif Uddin, MS, MSc, BSc⁵, Qasim Rana Khan, MBBS^6
1Cedars-Sinai Medical Center, Los Angeles, CA; ²Schulich School of Medicine and Dentistry, Western University, London, ON, Canada; ³Mayo Clinic College of Medicine and Science, Rochester, MN; ⁴Icahn School of Medicine at Mount Sinai, New York, NY; ⁵Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA; ⁶Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA

Introduction: Vedolizumab (VDZ) has demonstrated efficacy for the treatment of patients with moderate to severe ulcerative colitis (UC). Identifying similarities in baseline characteristics among patients who respond to VDZ could be valuable to establish the patient population that is most suitable for treatment with VDZ.

Methods: The baseline characteristics of patients with UC who responded to VDZ in the phase 3 clinical trials, GEMINI 1, VARSITY, and VISIBLE 1, and the phase 4 clinical trial, ENTERPRET, were pooled in order to identify similarities within the responder population. All four trials included adult patients with moderate to severe UC who had a prior inadequate response or loss of response to conventional therapies or anti-tumor necrosis factor alpha (anti-TNFα) treatment. Patients received VDZ 300 mg intravenously at weeks 0 and 2. The primary outcome was a response at week 6 defined as a decrease in partial Mayo score of ≥ 2 points and ≥ 25% from baseline, with a decrease in rectal bleeding sub-score of ≥ 1 or an absolute rectal bleeding sub-score of ≤ 1. Patient characteristics were analyzed using descriptive statistics, with mean or median values calculated across all four trials for continuous variables, and the number and proportion of responders reported for categorical variables.

Results: Of the total of 1,183 patients enrolled across the four trials, 989 (83.6%) were White, while Black or African American patients were the most underrepresented group (2.8%). At week 6, 783 patients (66.2%) had a clinical response to VDZ. The baseline characteristics of these responders are shown in Table 1. Of the VDZ responders, the mean disease duration was 7.4 years, and 24.5% had experienced previous treatment failure with anti-TNFα treatment. Most responders had left-sided colitis or pancolitis (Table 1), and the majority had moderate or severe disease at baseline (complete Mayo score category: moderate, n = 333 [42.5%]; severe, n = 440 [56.2%]). For rectal bleeding and stool frequency sub-scores, rectal bleeding with obvious blood in stool and 5 or more stools than normal were the most frequently observed categories at baseline, respectively (Table 1).

Discussion: These baseline characteristics of patients who respond to VDZ at 6 weeks may serve as an indicator to determine which patients are most likely to respond to VDZ treatment.



Disclosures:


Andres Yarur, MD¹, Vipul Jairath, MBChB, DPhil, MRCP², Edward V. Loftus, MD, FACG³, Bruce E. Sands, MD, MS, FACG⁴, Sharif Uddin, MS, MSc, BSc⁵, Qasim Rana Khan, MBBS⁶. B0387 - Baseline Demographics and Disease Characteristics of Patients With Ulcerative Colitis Who Responded to Vedolizumab at Week 6, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.